Page 229 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

208 PART 3 Therapeutic Modalities for the Cancer Patient

384. Ugurel S, Schadendorf D, Pfohler C, et al.: In vitro drug sensitiv- 387. Staunton JE, Slonim DK, Coller HA, et al.: Chemosensitivity
ity predicts response and survival after individualized sensitivity- prediction by transcriptional profiling, Proc Natl Acad Sci USA
directed chemotherapy in metastatic melanoma: a multicenter 98:10787–10792, 2001.
VetBooks.ir phase II trial of the dermatologic cooperative oncology group, Clin 388. Potti A, Dressman HK, Bild A, et al.: Retraction: genomic sig-
natures to guide the use of chemotherapeutics, Nat Med 17:135,
Cancer Res 12:5454–5463, 2006.
2011.
385. Staib P, Staltmeier E, Neurohr K, et al.: Prediction of individual
response to chemotherapy in patients with acute myeloid leukae- 389. Bonnefoi H, Potti A, Delorenzi M, et al.: Retraction—validation of
mia using the chemosensitivity index CI, Br J Haematol 128:783– gene signatures that predict the response of breast cancer to neoad-
791, 2005. juvant chemotherapy: a substudy of the EORTC 10994/big 00-01
386. Lee JK, Havaleshko DM, Cho H, et al.: A strategy for predicting clinical trial, Lancet Oncol 12:116, 2011.
the chemosensitivity of human cancers and its application to drug 390. Baggerly KA, Coombes KR: Deriving chemosensitivity from cell
discovery, Proc Natl Acad Sci USA 104:13086–13091, 2007. lines: forensic bioinformatics and reproducible research in high-
throughput biology, Ann Appl Stat 3:1309–1334, 2009.